Global Markets Direct’s pharmaceuticals report, “Sigmoid Pharma Ltd. - Product Pipeline Review - 2013” provides data on the Sigmoid Pharma Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Sigmoid Pharma Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Sigmoid Pharma Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
- Sigmoid Pharma Ltd. - Brief Sigmoid Pharma Ltd. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Sigmoid Pharma Ltd. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Sigmoid Pharma Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Sigmoid Pharma Ltd.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Sigmoid Pharma Ltd.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Sigmoid Pharma Ltd. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Sigmoid Pharma Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Sigmoid Pharma Ltd.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Sigmoid Pharma Ltd. and identify potential opportunities in those areas.
Table Of Contents
Sigmoid Pharma Ltd. - Product Pipeline Review - 2013 Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Sigmoid Pharma Ltd. Snapshot 5 Sigmoid Pharma Ltd. Overview 5 Key Information 5 Key Facts 5 Sigmoid Pharma Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 Sigmoid Pharma Ltd. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Sigmoid Pharma Ltd. - Pipeline Products Glance 11 Sigmoid Pharma Ltd. Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Sigmoid Pharma Ltd. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Sigmoid Pharma Ltd. - Drug Profiles 15 AlloCol 15 Product Description 15 Mechanism of Action 15 RandD Progress 15 cyclosporine IR 16 Product Description 16 Mechanism of Action 16 RandD Progress 16 CyCol 17 Product Description 17 Mechanism of Action 17 RandD Progress 17 CyCron 18 Product Description 18 Mechanism of Action 18 RandD Progress 18 Drug For Graft Versus Host Disease 19 Product Description 19 Mechanism of Action 19 RandD Progress 19 Drug For Neurodegeneration 20 Product Description 20 Mechanism of Action 20 RandD Progress 20 SmPill Enabled Combination Products 21 Product Description 21 Mechanism of Action 21 RandD Progress 21 Vaccine For Diarrhoea And Helicobacter Pylori Infections 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 Sigmoid Pharma Ltd. - Pipeline Analysis 23 Sigmoid Pharma Ltd. - Pipeline Products by Therapeutic Class 23 Sigmoid Pharma Ltd. - Pipeline Products By Target 25 Sigmoid Pharma Ltd. - Pipeline Products by Route of Administration 26 Sigmoid Pharma Ltd. - Pipeline Products By Mechanism of Action 27 Sigmoid Pharma Ltd. - Recent Pipeline Updates 28 Sigmoid Pharma Ltd. - Locations And Subsidiaries 29 Head Office 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables
Sigmoid Pharma Ltd., Key Information 5 Sigmoid Pharma Ltd., Key Facts 5 Sigmoid Pharma Ltd. - Pipeline by Indication, 2013 8 Sigmoid Pharma Ltd. - Pipeline by Stage of Development, 2013 9 Sigmoid Pharma Ltd. - Monotherapy Products in Pipeline, 2013 10 Sigmoid Pharma Ltd. - Phase II, 2013 11 Sigmoid Pharma Ltd. - Phase I, 2013 12 Sigmoid Pharma Ltd. - Preclinical, 2013 13 Sigmoid Pharma Ltd. - Discovery, 2013 14 Sigmoid Pharma Ltd. - Pipeline By Therapeutic Class, 2013 24 Sigmoid Pharma Ltd. - Pipeline By Target, 2013 25 Sigmoid Pharma Ltd. - Pipeline By Route of Administration, 2013 26 Sigmoid Pharma Ltd. - Pipeline Products By Mechanism of Action, 2013 27 Sigmoid Pharma Ltd. - Recent Pipeline Updates, 2013 28
List of Figures
Sigmoid Pharma Ltd. - Pipeline by Indication, 2013 7 Sigmoid Pharma Ltd. - Pipeline by Stage of Development, 2013 9 Sigmoid Pharma Ltd. - Monotherapy Products in Pipeline, 2013 10 Sigmoid Pharma Ltd. - Pipeline By Therapeutic Class, 2013 23 Sigmoid Pharma Ltd. - Pipeline Products By Mechanism of Action, 2013 27